<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>2022</volume><submitter>Zhang Y</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Fu fang Zhen Zhu Tiao Zhi (FTZ) is a patented preparation of Chinese herbal medicine that has been used as a natural medicine to treat several chronic diseases including cardiovascular disease. However, its effects on cardiac fibrosis remain unclear. Therefore, this study was designed to investigate the effects and potential mechanisms of FTZ in treating cardiac fibrosis.&lt;h4>Methods&lt;/h4>FTZ was administered to mice by oral gavage daily at a dosage of 1.2 g/kg or 2.4 g/kg of body weight for 7 weeks after a transverse aorta constriction (TAC) surgery. Doppler echocardiography, hematoxylin and eosin staining, and Masson's trichrome staining were used to assess the effect of FTZ on the cardiac structure and function of mice that had undergone TAC. EdU and wound-healing assay</pubmed_abstract><journal>Evidence-based complementary and alternative medicine : eCAM</journal><pagination>5642307</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9042631</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>The Traditional Chinese Medicine Formula FTZ Protects against Cardiac Fibrosis by Suppressing the TGF&lt;i>β&lt;/i>1-Smad2/3 Pathway.</pubmed_title><pmcid>PMC9042631</pmcid><pubmed_authors>Wu K</pubmed_authors><pubmed_authors>Yan M</pubmed_authors><pubmed_authors>Sun M</pubmed_authors><pubmed_authors>Shao X</pubmed_authors><pubmed_authors>Li Y</pubmed_authors><pubmed_authors>Guo J</pubmed_authors><pubmed_authors>Diao H</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Wang D</pubmed_authors><pubmed_authors>Huang X</pubmed_authors><pubmed_authors>Wang Z</pubmed_authors><pubmed_authors>Tang X</pubmed_authors></additional><is_claimable>false</is_claimable><name>The Traditional Chinese Medicine Formula FTZ Protects against Cardiac Fibrosis by Suppressing the TGF&lt;i>β&lt;/i>1-Smad2/3 Pathway.</name><description>&lt;h4>Background&lt;/h4>Fu fang Zhen Zhu Tiao Zhi (FTZ) is a patented preparation of Chinese herbal medicine that has been used as a natural medicine to treat several chronic diseases including cardiovascular disease. However, its effects on cardiac fibrosis remain unclear. Therefore, this study was designed to investigate the effects and potential mechanisms of FTZ in treating cardiac fibrosis.&lt;h4>Methods&lt;/h4>FTZ was administered to mice by oral gavage daily at a dosage of 1.2 g/kg or 2.4 g/kg of body weight for 7 weeks after a transverse aorta constriction (TAC) surgery. Doppler echocardiography, hematoxylin and eosin staining, and Masson's trichrome staining were used to assess the effect of FTZ on the cardiac structure and function of mice that had undergone TAC. EdU and wound-healing assay</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2025-04-26T04:04:39.36Z</modification><creation>2025-04-06T10:57:53.545Z</creation></dates><accession>S-EPMC9042631</accession><cross_references><pubmed>35497919</pubmed><doi>10.1155/2022/5642307</doi></cross_references></HashMap>